Engineering effective T-cell based antitumor immunity

OncoImmunology

Volumn 2, Issue 2, 2013, Pages

  Gruber, Thomas ^a   Hinterleitner, Reinhard ^a   Pfeifhofer Obermair, Christa ^a   Wolf, Dominik ^b   Baier, Gottfried ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Cancer immunotherapy; Cblb; Engineered t cells; Reinforced anti tumor functions; RNA interference

Indexed keywords

CASITAS B LINEAGE LYMPHOMA PROTO ONCOGENE PROTEIN B; DENDRITIC CELL VACCINE; GAMMA INTERFERON; MESSENGER RNA; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ADOPTIVE CELL TRANSFER; ADOPTIVE TRANSFER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CYTOKINE RELEASE; DRUG EFFICACY; ENZYME INACTIVATION; EX VIVO STUDY; GENE INACTIVATION; HUMAN; IMMUNOREACTIVITY; MOLECULAR DYNAMICS; NONHUMAN; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEPLETION; VALIDATION STUDY;

EID: 84886944711     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22893     Document Type: Note

References (9)

1. Hinterleitner R, Gruber T, Pfeifhofer-Obermair C, Lutz-Nicoladoni C, Tzankov A, Schuster M, et al. Adoptive transfer of siRNA cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model. PLoS One 2012; 7:e44295; PMID:22962608; http://dx.doi.org/10.1371/journal.pone.0044295.
2. Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, et al. CBLB regulates the CD28 dependence of T-cell activation. Nature 2000; 403:216-220; PMID:10646609; http://dx.doi.org/10.1038/35003235.
3. Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos-Santos A, et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor CBLB. Nature 2000; 403:211-216; PMID:10646608; http://dx.doi.org/10.1038/35003228.
4. Wohlfert EA, Gorelik L, Mittler R, Flavell RA, Clark RB. Cutting edge: deficiency in the E3 ubiquitin ligase cblb results in a multifunctional defect in T cell TGFbeta sensitivity in vitro and in vivo. J Immunol 2006; 176:1316-1320; PMID:16424156.
5. Wohlfert EA, Callahan MK, Clark RB. Resistance to CD4+CD25+ regulatory T cells and TGF-beta in cblb-/- mice. J Immunol 2004; 173:1059-1065; PMID:15240694.
6. Loeser S, Loser K, Bijker MS, Rangachari M, van der Burg SH, Wada T, et al. Spontaneous tumor rejection by cblb-deficient CD8+ T cells. J Exp Med 2007; 204:879-891; PMID:17403934; http://dx.doi.org/10.1084/jem.20061699.
7. Paolino M, Thien CB, Gruber T, Hinterleitner R, Baier G, Langdon WY, et al. Essential role of E3 ubiquitin ligase activity in CBLB-regulated T cell functions. J Immunol 2011; 186:2138-2147; PMID:21248250; http://dx.doi.org/10.4049/jimmunol.1003390.
8. Chiang JY, Jang IK, Hodes R, Gu H. Ablation of cblb provides protection against transplanted and spontaneous tumors. J Clin Invest 2007; 117:1029-1036; PMID:17364027; http://dx.doi.org/10.1172/JCI29472.
9. Lutz-Nicoladoni C, Wallner S, Stoitzner P, Pircher M, Gruber T, Wolf AM, et al. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine. Immunol Cell Biol 2012; 90:130-134; PMID:21383769; http://dx.doi.org/10.1038/icb.2011.11.